Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's MedImmune Gets Creative In Diabetes With PCSK9/GLP-1 Fusion Product

Executive Summary

AstraZeneca PLC's MedImmune LLC will be the first drug developer to present data for a "fusion molecule" therapy combining a PCSK9 antibody with a GLP-1 peptide when a Phase I trial of its pioneering product MEDI-4166 in type 2 diabetics completes later this year. The company's head of diabetes innovative medicines, Cristina Rondinone, explains to Scrip the thought process behind the unique combination and what to expect for further development of the novel drug in 2017.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097058

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel